PRMT5 and lymphoma: These results suggest that inhibition of PRMT5 in canine lymphoma can attenuate oncogenic MYC signaling while reactivating the RB tumor suppressor pathway and PRC2 silencing, an established mechanism of human lymphoma cell death after PRMT5 inhibition [37].